Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Asparaginase 10,000unit inj vials
0801050BUAAABAB
|
Asparaginase | Asparaginase | Malignant Disease and Immunosuppression | No data available |
|
Asparaginase 5,000unit inj vials
0801050BUAAAAAA
|
Asparaginase | Asparaginase | Malignant Disease and Immunosuppression | No data available |
|
Atriance 250mg/50ml solution for infusion vials
0801030ABBBAAAA
|
Atriance | Nelarabine | Malignant Disease and Immunosuppression | No data available |
|
Aubagio 14mg tablets
0802040ALBBAAAA
|
Aubagio | Teriflunomide | Malignant Disease and Immunosuppression | No data available |
|
Aubagio 7mg tablets
0802040ALBBABAB
|
Aubagio | Teriflunomide | Malignant Disease and Immunosuppression | No data available |
|
Avastin 100mg/4ml solution for infusion vials
0801050APBBAAAA
|
Avastin | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Avastin 400mg/16ml solution for infusion vials
0801050APBBABAB
|
Avastin | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Avelumab 200mg/10ml solution for infusion vials
0801050CFAAAAAA
|
Avelumab | Avelumab | Malignant Disease and Immunosuppression | No data available |
|
Avonex 30microgram inj vials
0802040M0BDAAAE
|
Avonex | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Avonex 30micrograms/0.5ml (6million units) inj pf pens
0802040M0BDACAM
|
Avonex | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Avonex 30micrograms/0.5ml (6million units) inj pfs
0802040M0BDABAF
|
Avonex | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Axitinib 1mg tablets
0801050BJAAAAAA
|
Axitinib | Axitinib | Malignant Disease and Immunosuppression | No data available |
|
Axitinib 3mg tablets
0801050BJAAADAD
|
Axitinib | Axitinib | Malignant Disease and Immunosuppression | No data available |
|
Axitinib 5mg tablets
0801050BJAAABAB
|
Axitinib | Axitinib | Malignant Disease and Immunosuppression | No data available |
|
Axitinib 7mg tablets
0801050BJAAACAC
|
Axitinib | Axitinib | Malignant Disease and Immunosuppression | No data available |
|
Aybintio 100mg/4ml solution for infusion vials
0801050APBDAAAA
|
Aybintio | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Aybintio 400mg/16ml solution for infusion vials
0801050APBDABAB
|
Aybintio | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Azacitidine 100mg powder for suspension for injection vials
0801030ACAAAAAA
|
Azacitidine | Azacitidine | Malignant Disease and Immunosuppression | No data available |
|
Azacitidine 150mg powder for suspension for injection vials
0801030ACAAACAC
|
Azacitidine | Azacitidine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 100mg/5ml oral solution
0802010G0AAAVAV
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 10mg/5ml oral liquid
0802010G0AAARAR
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 120mg/5ml oral liquid
0802010G0AABXBX
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 125mg/5ml oral liquid
0802010G0AAAXAX
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 12mg/5ml oral liquid
0802010G0AABSBS
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 13mg/5ml oral liquid
0802010G0AACECE
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.